Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Research

• Publication date

  2006-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-06-0190PMID 16818641
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.

  2006cited by this paper
• Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.

  2005cited by this paper
• The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

  2005influential reference
• Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.

  2005cited by this paper
• Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha.

  2005cited by this paper
• The TNF Family Members BAFF and APRIL Play an Important Role in Hodgkin Lymphoma.

  2005cited by this paper
• TACI and BCMA, Unlike BAFF-R, Are Expressed by Human Myeloma Cell Lines and TACI+ Cell Lines Have a Gene Signature Indicative of Mature Bone Marrow Plasma Cells and Bone Marrow Environment Dependence.

  2005cited by this paper
• The role of APRIL and BAFF in lymphocyte activation.

  2005cited by this paper
• Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.

  2005cited by this paper
• Novel model to evaluate changes in gene expression profile of myeloma cells in vivo following interaction with human BM microenvironment.

  2005cited by this paper
• Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors.

  2005cited by this paper
• Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

  2004cited by this paper
• Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway.

  2004cited by this paper
• Advances in biology of multiple myeloma: clinical applications.

  2004cited by this paper
• MIP-1 alpha and myeloma bone disease.

  2004cited by this paper
• BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

  2004cited by this paper
• Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.

  2004influential reference
• BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells

  2004influential reference
• BAFF AND APRIL: a tutorial on B cell survival.

  2003cited by this paper
• CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.

  2003cited by this paper
• Studies of Structure-Activity Relations of Complement Inhibitor Compstatin1

  2003cited by this paper
• Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

  2003cited by this paper
• Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor.

  2003cited by this paper
• EBV-Encoded Latent Membrane Protein 1 Cooperates with BAFF/BLyS and APRIL to Induce T Cell-Independent Ig Heavy Chain Class Switching 1

  2003cited by this paper
• Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma.

  2002cited by this paper
• Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.

  2002cited by this paper
• A molecular compendium of genes expressed in multiple myeloma.

  2002cited by this paper
• BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells

  2002cited by this paper
• BAFF: A fundamental survival factor for B cells

  2002cited by this paper
• CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells.

  2002cited by this paper
• NF-kappa B as a therapeutic target in multiple myeloma.

  2002cited by this paper
• BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells.

  2002cited by this paper
• NF-κB as a Therapeutic Target in Multiple Myeloma*

  2002cited by this paper
• Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.

  2001cited by this paper
• TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3 and Activates NF-κB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase1

  2000cited by this paper
• TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

  2000cited by this paper
• Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity

  2000cited by this paper
• BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth

  1999cited by this paper
• BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.

  1999cited by this paper
• Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.

  1996cited by this paper
• BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes.

  1995cited by this paper
• Generation of functional clonal cell lines from human bone marrow stroma.

  1985cited by this paper

• Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma.

  2025cites this paper
• Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: where do we stand today?

  2024cites this paper
• TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma

  2024cites this paper
• Bispecific Antibodies in the Treatment of Multiple Myeloma.

  2024cites this paper
• Current status of BAFF targeting immunotherapy in B-cell neoplasm

  2024cites this paper
• Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma

  2024cites this paper
• An IL-1β-driven neutrophil–stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma

  2024cites this paper
• Modelling Myeloma Dissemination in vitro with hMSC-Interacting Subpopulations of INA-6 Cells and their Aggregation/Detachment Dynamics.

  2024cites this paper
• Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma

  2024cites this paper
• The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease

  2024cites this paper
• Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus

  2024cites this paper
• The BAFF-APRIL System in Cancer

  2023cites this paper
• Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma

  2023cites this paper
• Role of NF-κB Signaling in the Interplay between Multiple Myeloma and Mesenchymal Stromal Cells

  2023cites this paper
• Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing

  2023cites this paper
• Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

  2023cites this paper
• The Research Advances of Aptamers in Hematologic Malignancies

  2023cites this paper
• Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry

  2023cites this paper
• An IL-1β driven neutrophil-stromal cell axis fosters a BAFF-rich microenvironment in multiple myeloma

  2023cites this paper
• Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma

  2022cites this paper
• Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen

  2022cites this paper
• Pathogenic signaling in multiple myeloma.

  2022cites this paper
• B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages

  2022cites this paper
• BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice

  2022cites this paper
• Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma

  2022cites this paper
• Inhibition of BCMA signaling alters protein translation and Multiple Myeloma growth

  2021cites this paper
• The Pathophysiology of Myeloma Bone Disease: Bone Remodelling and the Role of Osteoclasts

  2021cites this paper
• Myeloma Bone Disease: A Comprehensive Review

  2021cites this paper
• Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma

  2021cites this paper
• Chimeric Antigen Receptor T Cells for Multiple Myeloma

  2021cites this paper
• ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment

  2021cites this paper
• Title : Aberrant BCMA Signaling Promotes Tumor Growth by Altering Protein Translation Machinery , a Therapeutic Target for the Treatment of Relapse / Refractory Multiple Myeloma

  2021cites this paper
• TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas

  2021cites this paper
• The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research

  2021cites this paper
• Novel Experimental Drugs for Treatment of Multiple Myeloma

  2021influential citation
• An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy.

  2021cites this paper
• The clinical potential of gene editing as a tool to engineer cell-based therapeutics

  2020cites this paper
• BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma

  2020cites this paper
• CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions

  2020cites this paper
• Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma?

  2020influential citation
• Targeting Multiple Myeloma through the Biology of Long-Lived Plasma Cells

  2020cites this paper
• Vascular and Stromal Contributions to Tumor Bone-Homing: Focus on Multiple Myeloma

  2020cites this paper
• Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma

  2020cites this paper
• The role of bone marrow stromal cells in blood diseases and clinical significance as a crucial part of the hematopoietic microenvironment

  2020cites this paper
• Immunotherapeutic Strategies for Multiple Myeloma

  2020cites this paper
• Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma

  2020cites this paper
• Targeting NF-κB Signaling for MM

  2020cites this paper
• Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma

  2020cites this paper
• Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma.

  2020cites this paper
• Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021

  2020cites this paper
• Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.

  2020cites this paper
• BCMA-targeted immunotherapy for multiple myeloma

  2020cites this paper
• A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma

  2020cites this paper
• Targeting NF-κB Signaling for Multiple Myeloma

  2020cites this paper
• Natural killer cells, multiple myeloma, and daratumumab : a love-hate relationship

  2019cites this paper
• Microbial antigens-loaded myeloma cells enhance Th2 cell proliferation and myeloma clonogenicity via Th2–myeloma cell interaction

  2019cites this paper
• Multiple myeloma-derived exosomes inhibit osteoblastic differentiation and improve IL-6 secretion of BMSCs from multiple myeloma

  2019cites this paper
• An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery

  2019cites this paper
• B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma

  2019cites this paper
• Multiple Myeloma Bone Disease

  2019cites this paper
• Investigations into the protective effects of the Multiple Myeloma Bone Marrow Microenvironment

  2018cites this paper
• Bone-targeted agents in multiple myeloma

  2018cites this paper
• Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma

  2018cites this paper
• Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update

  2018cites this paper
• Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma.

  2018cites this paper
• An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.

  2018cites this paper
• Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets

  2018cites this paper
• APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications

  2018cites this paper
• The NF-κB Activating Pathways in Multiple Myeloma

  2018cites this paper
• Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

  2018cites this paper
• Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

  2018cites this paper
• Clinical impact of serum soluble SLAMF7 in multiple myeloma

  2018cites this paper
• Inhibiting γ-secretase in myeloma tumor cells to improve killing by chimeric antigen receptor T cells

  2017cites this paper
• Myeloma and Bone Disease

  2017cites this paper
• New monoclonal antibodies on the horizon in multiple myeloma

  2017cites this paper
• BAFF is involved in macrophage-induced bortezomib resistance in myeloma

  2017influential citation
• Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

  2017cites this paper
• Monoclonal antibody therapy in multiple myeloma

  2017cites this paper
• Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing

  2017cites this paper
• Myeloma bone disease: pathogenesis and treatment.

  2017cites this paper
• PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment

  2017cites this paper
• Immunotherapy for the treatment of multiple myeloma.

  2017cites this paper
• Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.

  2017cites this paper
• Running title: Classical/Alternative NFkB pathways in MM

  2017cites this paper
• Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

  2017cites this paper
• Multiple Myeloma: Treatment is Getting Individualized.

  2016cites this paper
• Surface-tension driven open microfluidic platform for hanging droplet culture.

  2016cites this paper
• Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells

  2016cites this paper
• Improved quantitative measurement of translocation of NF-κB in human activated B cells by confocal microscopy

  2016cites this paper
• Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma

  2016cites this paper
• Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

  2016cites this paper
• Development of Novel Immunotherapies for Multiple Myeloma

  2016cites this paper
• Development of chimeric antigen receptors for multiple myeloma.

  2016cites this paper
• LYMPHOID NEOPLASIA APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

  2016cites this paper
• Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

  2016cites this paper
• Targeting the Bone Marrow Microenvironment.

  2016cites this paper
• Bone Disease in Multiple Myeloma.

  2016cites this paper
• miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor

  2016cites this paper
• microRNA-202激活JNK/SAPK信号通路增强多发性骨髓瘤细胞药物敏感性的研究

  2016cites this paper
• MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment

  2016cites this paper